Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Thalamic-Burst-DBS for Neuropathic Pain

NCT: NCT05204472 · RECRUITING

NCT IDNCT05204472
StatusRECRUITING
Start Date2022-09-01
Completion2027-02

Brief Summary

Central post-stroke pain (CPSP) is a neuropathic pain syndrome and one of the major sequelae after ischemic or hemorrhagic cerebral stroke. Recently, a modified stimulation paradigm has been developed in the field of spinal cord stimulation (SCS) for a variety of neuropathic pain disorders. To date, this stimulation paradigm has not yet been evaluated systematically for deep brain stimulation to treat neuropathic pain disorders. The purpose of this clinical investigation is to investigate if Burst-DBS of the thalamus is more effective compared to classical continuous low-frequency stimulation DBS to reduce the subjective pain intensity in patients with chronic neuropathic pain after stroke or in patients with neuropathic facial pain.

Frequently Asked Questions

What is Thalamic-Burst-DBS for Neuropathic Pain?

Thalamic-Burst-DBS for Neuropathic Pain is a clinical trial registered under NCT05204472. Current status: RECRUITING.

What is the status of NCT05204472?

The current status of NCT05204472 (Thalamic-Burst-DBS for Neuropathic Pain) is: RECRUITING.

When did Thalamic-Burst-DBS for Neuropathic Pain start?

Thalamic-Burst-DBS for Neuropathic Pain started on 2022-09-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.